https://www.selleckchem.com/products/tph104m.html
Overall, this study establishes PV3 to be CD22 binding peptide with proven effectiveness as a targeting element. In future, the optimal TNPPV3 formulation will potentially achieve maximal in vivo therapeutic outcomes by efficiently targeting CD22+ blood cancer cells in vivo.Herein we report the successful exfoliation of few-layer BP (FL-BP) from bulk BP via ultrasonication in N-methylpyrrolidone (NMP). FL-BP exhibited an orthorhombic phase structure similar to that of bulk BP with weak electrostatic out-of-plane interactions and strong
Like
Comment
Share
